Lymphoma — ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Citation(s)
A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies